Sacituzumab Govitecan Sustains Clinical Activity in Patients With Heavily Pretreated mUC
September 20th 2020Final results from cohort 1 of the phase 3 TROPHY-U-01 trial reported continued significant activity with sacituzumab govitecan-hziy as treatment of patients with metastatic urothelial carcinoma who progressed on both platinum-based chemotherapy and checkpoint inhibition.
Veliparib Combination Induces Significant Improvement in PFS for BRCA-Like Advanced TNBC
June 3rd 2020“With demonstration of efficacy in biomarker-selected BRCA-like phenotype triple-negative breast cancer, the results of this trial are a very positive step toward expanding the role of PARP inhibitors beyond germline BRCA in breast cancer."
Updated Data Displays Better OS With Use of Alectinib Over Crizotinib in ALK+ NSCLC
May 31st 2020Patients with ALK-positive non–small cell lung cancer showed clinically meaningful improvement in overall survival when receiving alectinib, a highly selective second-generation TKI, versus those treated with crizotinib, according to updated data from the pivotal phase 3 ALEX trial presented at the 2020 ASCO Virtual Scientific Program.
HER2+ Colorectal and Gastric/GEJ Cancers Demonstrate Responses to Fam-Trastuzumab Deruxtecan Therapy
May 30th 2020Data from 2 phase 2 trials involving fam-trastuzumab deruxtecan-nxki revealed the agent’s ability to induce responses in patients with HER2-positive metastatic colorectal cancer and advanced gastric or gastroesophageal junction adenocarcinoma.
Vemurafenib/Cobimetinib Plus Atezolizumab Combo Improves PFS in Advanced Melanoma
May 3rd 2020"Atezolizumab combined with vemurafenib and cobimetinib showed a statistically significant and clinically meaningful in progression-free survival via investigator assessment when compared with placebo plus vemurafenib and cobimetinib."
Novel Agents Continue to Advance in the Treatment Landscape of DLBCL
February 28th 2020Because diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma in the US, clinical investigators are eager to make progress with novel agents, despite recent advances, said Craig Moskowitz, MD, in a presentation during the 2020 International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myeloma.<br />
The Importance of Molecular Monitoring in the Treatment of AML
November 13th 2019In an interview with Targeted Oncology, Eytan M. Stein, MD, reviews the current treatment landscape of acute myeloid leukemia, underscores the importance of molecular monitoring, and highlights where the field is headed.
Expert Predicts Immunotherapy Combos Will Transform Treatment in Multiple Myeloma
October 8th 2019<br /> In the future, we’re going to do combination therapies. They will be used in a subset of patients better defined by profiling,” Kenneth C. Anderson, MD, told an audience at the Charlotte Plasma Cell Disorder Congress in North Carolina.
New Myeloma Induction Leads to Better Survival
October 7th 2019Successful induction regimens can reduce the burden of disease and prolong the durability of treatment response, time to disease progression, and overall survival for patients with newly diagnosed multiple myeloma, all while minimizing toxicity, according to Saad Usmani, MD, chief of the Plasma Cell Disorders Program and director of clinical research in hematologic malignancies at Levine Cancer Institute of the Carolinas Medical Center in Charlotte, North Carolina.
Encouraging Responses Seen With TIL Therapy in Advanced Cervical Cancer
September 4th 2019In an interview with Targeted Oncology, Amir A. Jazaeri, MD, discussed the role of LN-145 in cervical cancer. He also highlighted next steps for this treatment approach and the promise of TIL therapy in cervical cancer, as well as other tumor types.
Prefilled Syringe of Lanreotide Approved for GEP-NETs by FDA
June 25th 2019A prefilled syringe of lanreotide has been approved by the FDA to enable healthcare providers to administer the injection easier to adults with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors.
Study Finds Synergism With Olaparib/Neratinib Combo in HER2+ Uterine Serous Carcinoma
May 6th 2019In new preclinical data, the combination of the PARP inhibitor olaparib (Lynparza) and the pan-HER TKI neratinib (Nerlynx) was found to be highly synergistic in HER2-positive uterine serous carcinoma, according to lead study author Ghanshyam Yadav, MD.
Study Solidifies Confidence in Liquid Biopsies for Faster Biomarker Detection in NSCLC, Expert Says
April 17th 2019In addition to confirming the utility of liquid biopsies to reliably detect guideline-recommended biomarkers in patients with stage IV NSCLC, findings from the NILE study also showed liquid biopsies have a quicker turnaround time compared with standard tissue-based assays, said senior study author Vassiliki A. Papadimitrakopoulou, MD.
IO Combo Induces Responses in High-Grade Neuroendocrine Carcinoma
April 1st 2019An immunotherapy combination led to a response rate of 44% in patients with high-grade neuroendocrine carcinoma, according to the results of a phase II trial presented at the 2019 AACR Annual Meeting. Nivolumab in combination with ipilimumab was also well tolerated among patients, the results of the DART study showed.
FDA Proposes Updates to Mammography Standards for First Time in 20 Years
March 28th 2019In an effort to enable healthcare providers and patients to make more informed medical decisions, the FDA has proposed amendments to key policies to modernize breast cancer screening and improve mammography services.
Ibrutinib Survival Outcomes in MCL Consistent in Real-World Setting, But Questions Remain
March 11th 2019Jeff Sharman, MD, discusses the implications of real-world ibrutinib findings in mantle cell lymphoma and underscored the need for the development of more effective treatments for this patient population.
Medicare Makes Move Toward CAR T-Cell Therapy Coverage
February 19th 2019To date, there is no national Medicare policy in place to provide coverage for CAR T-cell therapies, which have been proven to be a successful treatment for certain patients with relapsed/refractory cancers. Now, the Centers for Medicare & Medicaid Services has proposed to cover CAR T-cell therapies approved by the FDA under “Coverage with Evidence Development."
Survival Benefit With GI-Based Adjuvant Chemotherapy Regimen in Mucinous Ovarian Cancer
February 5th 2019Data from a retrospective study suggests an adjuvant gastrointestinal-based chemotherapy regimen is more beneficial than one that is gynecologic-based in patients with mucinous ovarian cancer, said Katherine C. Kurnit, MD.
Progress in Treating Rare Cancers Named ASCO's Advance of the Year
February 4th 2019In recognition of the many advancements that have been made in the past year toward developing new therapies for patients with difficult-to-treat, rare cancers, ASCO has chosen progress in treating rare cancers as its Advance of the Year.
Expert Discusses Recent Advances With PARP Inhibitors in Ovarian Cancer
February 4th 2019In an interview with <em>Targeted Oncology</em> during the 2019 SGO Annual Winter Meeting, Shannon Westin, MD, discussed the advances seen with PARP inhibitors in ovarian cancer, novel investigational agents, and the importance of molecular testing.